Iopentol (Imagopaque®) in vascular procedures A multi-centre monitoring trial assessing adverse events and diagnostic information – results from 3,587 patients in Germany C.-P. MuthP. HensekeB. H. Grynne Pages: S104 - S108
Iopentol (Imagopaque® 300) compared with iopromide (Ultravist® 300) in abdominal CT A multi-centre monitoring trial assessing adverse events and diagnostic information – results from 518 patients in Spain J. L. EncinaL. Martí-BonmatíV. Rodríguez Pages: S115 - S119
Iopentol (Imagopaque® 350) compared with iohexol (Omnipaque® 350) in pediatric cardioangiography A clinical trial assessing adverse events, ECG, blood pressure and diagnostic information M. KunnenD. De GreefK. Skinningsrud Pages: S123 - S126
Oral administration of iopentol (Imagopaque® 300 mg I/ml) compared with amidotrizoate (Peritrast® 300 mg I/ml), both diluted to 2 % (v/v), in imaging of the gastrointestinal tract in abdominal contrast enhanced CT A clinical trial assessing patient tolerance, distribution of contrast medium and Hounsfield unit measurements J. M. FriedrichK. SkinningsrudE. Merkle Pages: S140 - S144
Iopentol (Imagopaque® 250) compared with diatrizoate (Urografin® 219) in endoscopic retrograde cholangio-pancreatography (ERCP) A clinical trial assessing safety (adverse events and S-pancreatic iso-amylase) and diagnostic information (VAS) A. KruseA. BrockK. Bjartveit Pages: S131 - S134
Delayed CT of the kidneys after iopentol (Imagopaque® 350) injection in patients with normal renal function An assessment of the gradual decrease in opacification over 32 h after injection D. RickardsJ. Å. JakobsenP. Kjærsgaard Pages: S149 - S151
Cardiovascular and electrocardiographic effects of iopentol in left ventricular angiography Comparison of the low-osmolar, non-ionic iopentol (Imagopaque® 350) and the hyper-osmolar, ionic metrizoate meglumine-Na-Ca (Isopaque® Coronar 370) in patients with coronary heart disease H. Vik-MoR. DanielsenA. Bjørkhaug Pages: S156 - S161
Evaluation of iopentol (Imagopaque® 350) in CT enhancement A multi-centre monitoring trial assessing adverse events and diagnostic information – results from 1,823 patients in France M. OxaalM. LambrechtsJ. F. Menuet Pages: S109 - S114
Iopentol (Imagopaque® 300) compared with iohexol (Omnipaque® 300) and diatrizoate (Urografin® 292) in pediatric urography A clinical trial assessing adverse events and diagnostic information P. LanningO. Brekke Pages: S120 - S122
Iopentol (Imagopaque® 300) compared with ioxaglate (Hexabrix® 320) in knee arthrography A clinical trial assessing immediate and late adverse events and diagnostic information J. J. RailhacO. Brekke Pages: S135 - S139
Iopentol (Imagopaque® 300) compared with iopromide (Ultravist® 300) in pediatric angiocardiography A clinical trial assessing adverse events, ECG and diagnostic information J. F. PiéchaudL. IserinK. Skinningsrud Pages: S127 - S130
Iopentol (Imagopaque® 350) compared with diatrizoate (Urografin® 370) in cerebral CT A clinical trial assessing immediate and late (7 days) adverse events and diagnostic information (visualization quality and Hounsfield unit measurements) A. ValentineJ. Å. JakobsenA. J. Klaveness Pages: S145 - S148
Iopentol (Imagopaque® 300 and 350) compared with iohexol (Omnipaque® 300 and 350) in cerebral and aortic arch angiography A clinical trial assessing adverse events and diagnostic information K. EricssonK. Bjartveit Pages: S152 - S155
